<DOC>
	<DOC>NCT01365494</DOC>
	<brief_summary>This study was planned to establish the non-inferiority of Rabipur administered as simulated post exposure Zagreb schedule as compared to Essen schedule, in healthy Indian adult subjects.</brief_summary>
	<brief_title>Immunogenicity and Safety of Rabies Vaccine, Administered With Two Different Simulated Post Exposure Schedules</brief_title>
	<detailed_description />
	<mesh_term>Rabies</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>1. Males and females of age ≥ 18 years. 2. Individuals who had given written consent. 3. Individuals in good health and available for all the visits scheduled in the study. 1. Pregnancy or unwillingness to practice acceptable contraception. 2. A history of Rabies vaccination. 3. History of allergy to egg protein. 4. Known hypersensitivity to neomycin, tetracycline, amphotericinB or any other vaccine component. 5. A significant acute or chronic infectious disease or use of antibiotics that may impact the subject's safety and /or immunogenicity in the Investigators opinion at the time of enrolment. 6. Body temperature ≥38.0°C (≥ 100.4°F) within 3 days of study vaccination. 7. Treatment with an antimalarial drug, up to two months prior to the study. 8. Individuals who received any other vaccines within 28 days prior to enrollment. 9. Subjects who have received blood, blood products and/or plasma derivatives or any parenteral immunoglobulin preparation in the past 12 weeks. 10. Any planned surgery during the study period. 11. Subjects who have cancer disorders excluding nonmelanotic skin cancer.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Rabies</keyword>
	<keyword>rabies vaccines</keyword>
	<keyword>post-exposure prophylaxis</keyword>
</DOC>